Claims
- 1. A method for detecting the presence or concentration of glucose in a sample which may also contain an alpha-hydroxy acid or a beta-diketone, which comprises:
a) exposing the sample to a compound having at least two recognition elements for glucose, oriented such that the interaction between the compound and glucose is more stable than the interaction between the compound and the alpha-hydroxy acid or beta-diketone, said compound also containing a detectable moiety having a detectable quality that changes in a concentration-dependent manner when said compound is exposed to glucose in said sample; and b) measuring any change in said detectable quality to thereby determine the presence or concentration of glucose in said sample, wherein the presence of the alpha-hydroxy acid or the beta-diketone does not substantially interfere with said determination.
- 2. The method of claim 1, wherein the compound has the following structure:
- 3. The method of claim 2, wherein R8 is selected from the group consisting of boronic acid, boronate ion, arsenious acid, arsenite ion, telluric acid, tellurate ion, germanic acid, germanate ion, and combinations thereof.
- 4. The method of claim 3, wherein each R8 is a boronic acid group.
- 5. The method of claim 2, wherein the compound comprises at least two detectable moieties that are capable of energy transport from one to the other, and wherein said energy transport is modulated by the presence of glucose in the sample.
- 6. The method of claim 2, wherein at least one of R, R1, R2, R4, R5, R9 or R10 comprises a fluorophore moiety and further wherein at least one of those groups comprises a quenching moiety, and wherein said fluorophore is either quenched or dequenched when said compound interacts with glucose in the sample.
- 7. The method of claim 2, wherein the compound comprises a fluorophore, and the fluorescence of said fluorophore is modulated by the interaction of said compound with glucose.
- 8. The method of claim 1, wherein the sample is a physiological fluid.
- 9. The method of claim 8, wherein the physiological fluid is selected from the group consisting of blood, plasma, serum, interstitial fluid, cerebrospinal fluid, urine, saliva, intraocular fluid, lymph, tears, sweat, and physiological buffers.
- 10. The method of claim 1, wherein the compound is exposed to the sample in solution.
- 11. The method of claim 1, wherein the compound is immobilized on or within a solid support.
- 12. The method of claim 11, wherein the solid support is a polymeric matrix.
- 13. The method of claim 1, wherein the compound is associated with an implantable device, and wherein step a) take place in vivo.
- 14. The method of claim 2, wherein R is an anthracene residue; R1, R2, R3, R4 and R5 are hydrogen; R6 and R7 are dimethylamine residues; each R8 is a boronic acid group; R9 and R10 are aliphatic carboxylic acid residues; and each Z is carbon.
- 15. The method of claim 14, wherein R9 and R10 are propionic acid residues.
- 16. The method of claim 2, wherein R is a hexamethylene residue; R1, R2, R3, R4 and R5 are hydrogen; R6 and R7 are dimethylamine residues; each R6 is a boronic acid group; R9 is a naphthalimide residue; R10 is a dimethylaminobenzyl residue; and each Z is carbon.
- 17. The method of claim 2, wherein R is an anthracene residue; R1, R2, R3, R4 and R5 are hydrogen; R6 and R7 are dimethylamine residues; each R8 is a boronic acid group; R9 and R10 are the same or different and are selected from the group consisting of a methacrylamidoalkyl residue, a methacroyloxyethoxyalkyl residue, a hydroxyethoxyalkyl residue, and an aminoalkyl residue; and each Z is carbon.
- 18. The method of claim 2, wherein the compound is selected from the group consisting of:
9-[N-(2-boronobenzyl)-N-[2-(2-methacroyloxyethoxy)ethylamino]methyl]-10-[N-(2-boronobenzyl)-N-[2-(2-hydroxyethoxy)ethylamino]methyl]anthracene; 9,10-bis[N-(2-boronobenzyl)-N-[3-(propanoyl)amino]methyl]anthracene; 9,10-bis[N-(2-boronobenzyl)-N-[3-(methacrylamido)propylamino]methylanthracene; 9-[N-(2-boronobenzyl)-N-[3-(methacrylamido)propylamino]methyl]-10-[N-(2-boronobenzyl)-N-[2-(2-hydroxyethoxy)ethylamino]methyl]anthracene; 9,10-bis[N-(2-boronobenzyl)-N-[2-(2-methacroyloxyethoxy)ethylamino]methyl]anthracene; and 9,10-bis[N-(2-boronobenzyl)-N-[5-aminopentylamino]methyl]anthracene, and salts thereof.
- 19. A compound having the following structure
- 20. The compound of claim 19, wherein R8 is selected from the group consisting of boronic acid, boronate ion, arsenious acid, arsenite ion, telluric acid, tellurate ion, germanic acid, germanate ion, all optionally protected, and combinations thereof.
- 21. The compound of claim 20, wherein each R8 is an optionally protected boronic acid group.
- 22. The compound of claim 19, wherein the compound comprises a fluorophore, and the fluorescence of said fluorophore is modulated by the interaction of said compound with glucose.
- 23. The compound of claim 19, wherein R is an anthracene residue; R1, R2, R3, R4 and R5 are hydrogen; R6 and R7 are dimethylamine residues; each R8 is an optionally protected boronic acid group; R9 and R10 are aliphatic carboxylic acid residues; and each Z is carbon.
- 24. The compound of claim 23, wherein R9 and R10 are propionic acid residues.
- 25. The compound of claim 1, wherein R is an anthracene residue; R1, R2, R3, R4 and R5 are hydrogen; R6 and R7 are dimethylamine residues; each R8 is an optionally protected boronic acid group; R9 and R10 are the same or different and are selected from the group consisting of a methacrylamidoalkyl residue, a methacroyloxyethoxyalkyl residue, a hydroxyethoxyalkyl residue, and an aminoalkyl residue; and each Z is carbon.
- 26. The compound of claim 19, wherein the compound is selected from the group consisting of:
9-[N-[2-(5,5-dimethylborinan-2-yl)benzyl]-N-[2-(2-methacroyloxyethoxy)ethylamino]methyl]-10-[N-[2-(5,5-dimethylborinan-2-yl)benzyl]-N-[2-(2-hydroxyethoxy)ethylamino]-methyl]anthracene; 9-[N-(2boronobenzyl)-N-[2-(2-methacroyloxyethoxy)ethylamino]methyl]-10-[N-(2-boronobenzyl)-N-[2-(2-hydroxyethoxy)ethylamino]methyl]anthracene; 9,10-bis[N-(2-boronobenzyl)-N-[3-(propanoyl)amino]methyl]anthracene; 9,10-bis[N-[2-(5,5-dimethylborinan-2-yl)benzyl]-N-[3-(methacrylamido)propylamino]methylanthracene; 9,10-bis[N-(2-boronobenzyl)-N-[3-(methacrylamido)propylamino]methylanthracene; 9-[N-[2-(5,5-dimethylborinan-2-yl)benzyl]-N-[3-(methacrylamido)propylamino]methyl]-10-[N-[2-(5,5-dimethylborinan-2-yl)benzyl]-N-[2-(2-hydroxyethoxy)ethylamino]methyl]anthracene; 9-[N-(2-boronobenzyl)-N-[3-(methacrylamido)propylamino]methyl]-10-[N-(2-boronobenzyl)-N-[2-(2-hydroxyethoxy)ethylamino]methyl]anthracene; 9,10-bis[N-[2-(5,5-dimethylborinan-2-yl)benzyl]-N-[2-(2-methacroyloxyethoxy)ethylamino]methyl]anthracene; 9,10-bis[N-(2-boronobenzyl)-N-[2-(2-methacroyloxyethoxy)ethylamino]methyl]anthracene; and 9,10-bis[N-(2-boronobenzyl)-N-[5-aminopentylamino]methyl]anthracene, and salts thereof.
- 27. A detection system for detecting the presence or concentration of glucose in a sample which may also contain an alpha-hydroxy acid or a beta-diketone, which comprises a compound having the following structure
- 28. The detection system of claim 27, wherein R8 is selected from the group consisting of boronic acid, boronate ion, arsenious acid, arsenite ion, telluric acid, tellurate ion, germanic acid, germanate ion, all optionally protected, and combinations thereof.
- 29. The detection system of claim 28, wherein each R8 is an optionally protected boronic acid group.
- 30. The detection system of claim 27, wherein the compound comprises a fluorophore, and the fluorescence of said fluorophore is modulated by the interaction of said compound with glucose.
- 31. The detection system of claim 27, wherein R is an anthracene residue; R1, R2, R3, R4 and R5 are hydrogen; R6 and R7 are dimethylamine residues; each R8 is an optionally protected boronic acid group; R9 and R10 are aliphatic carboxylic acid residues; and each Z is carbon.
- 32. The detection system of claim 31, wherein R9 and R10 are propionic acid residues.
- 33. The detection system of claim 27, wherein R is an anthracene residue; R1, R2, R3, R4 and R5 are hydrogen; R6 and R7 are dimethylamine residues; each R8 is a boronic acid group; R9 and R10 are the same or different and are selected from the group consisting of a methacrylamidoalkyl residue, a methacroyloxyethoxyalkyl residue, a hydroxyethoxyalkyl residue, and an aminoalkyl residue; and each Z is carbon.
- 34. The detection system of claim 27, wherein the compound is selected from the group consisting of:
9-[N-[2-(5,5-dimethylborinan-2-yl)benzyl]-N-[2-(2-methacroyloxyethoxy)ethylamino]methyl]-10-[N-[2-(5,5-dimethylborinan-2-yl)benzyl]-N-[2-(2-hydroxyethoxy)ethylamino]-methyl]anthracene; 9-[N-(2-boronobenzyl)-N-[2-(2-methacroyloxyethoxy)ethylamino]methyl]-10-[N-(2-boronobenzyl)-N-[2-(2-hydroxyethoxy)ethylamino]methyl]anthracene; 9,10-bis[N-(2-boronobenzyl)-N-[3-(propanoyl)amino]methyl]anthracene; 9,10-bis[N-[2-(5,5-dimethylborinan-2-yl)benzyl]-N-[3-(methacrylamido)propylamino]methylanthracene; 9,10-bis[N-(2-boronobenzyl)-N-[3-(methacrylamido)propylamino]methylanthracene; 9-[N-[2-(5,5-dimethylborinan-2-yl)benzyl]-N-[3-(methacrylamido)propylamino]methyl]-10-[N-[2-(5,5-dimethylborinan-2-yl)benzyl]-N-[2-(2-hydroxyethoxy)ethylamino]methyl]anthracene; 9-[N-(2-boronobenzyl)-N-[3-(methacrylamido)propylamino]methyl]-10-[N-(2-boronobenzyl)-N-[2-(2-hydroxyethoxy)ethylamino]methyl]anthracene; 9,10-bis[N-[2-(5,5-dimethylborinan-2-yl)benzyl]-N-[2-(2-methacroyloxyethoxy)ethylamino]methyl]anthracene; 9,10-bis[N-(2-boronobenzyl)-N-[2-(2-methacroyloxyethoxy)ethylamino]methyl]anthracene; and 9,10-bis[N-(2-boronobenzyl)-N-[5-aminopentylamino]methyl]anthracene, and salts thereof.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation-in-part of application Ser. No. 09/754,217 filed Jan. 5, 2001 and claims the benefit of application Ser. No. 60/329,746 filed Oct. 18, 2001 and application Ser. No. 60/269,887 filed Feb. 21, 2001.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60329746 |
Oct 2001 |
US |
|
60269887 |
Feb 2001 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09754217 |
Jan 2001 |
US |
Child |
10029184 |
Dec 2001 |
US |